Oxidized SOD1 accelerates cellular senescence in stem cells

The use of a peptide targeting misfolded SOD1 for lysosomal degradation in stem cells addresses the issue of cellular senescence by reducing senescence markers and enhancing proliferation, improving the quality and regenerative potential of stem cells.

WO2024234076A1PCT designated stage expired Publication Date: 2024-11-21UNIVERSITY OF MANITOBA
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
PCT/CA2024/050536
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-15
Filing Date
2024-04-24
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Adult neural stem cells (NSCs) undergo cellular senescence due to accumulation of protein aggregates, leading to reduced proliferative capacity and regenerative functions, with oxidized superoxide dismutase 1 (SOD1) contributing to this process by triggering aberrant misfolding and protein aggregation, and its removal is crucial for rejuvenating NSCs and improving the quality of human mesenchymal stem cells for therapeutic applications.

Method used

A method involving the use of a peptide with a lysosomal targeting motif and a derlin-binding region specific for superoxide dismutase 1, which penetrates cells and directs misfolded SOD1 to lysosomes for degradation, thereby reducing senescence markers and enhancing proliferation in NSCs and mesenchymal stem cells.

Benefits of technology

The selective removal of oxidized SOD1 using this peptide approach significantly reduces biomarkers of cellular senescence, increases proliferation, and improves the quality and production of stem cells, mitigating the toxic effects of extracellular vesicles containing misfolded SOD1, thus rejuvenating NSCs and maintaining the regenerative potential of hBMSCs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CA2024050536_21112024_PF_FP_ABST
    Figure CA2024050536_21112024_PF_FP_ABST
Patent Text Reader

Abstract

NSCs expressing the full length human SOD1 increasingly express biomarkers of cellular senescence with repeated passages in vitro. In this process, levels of misfolded hSOD1 in the NSCs increase with the increased number of passages. Selective removal of misfolded SOD1 from NSCs remarkably increases proliferation and sternness of NSCs. Our study also reveals that extracellular vesicles (EVs) derived from senescent NSCs expressing the wild type hSOD1 contain high level of misfolded SOD1 that is oxidized and toxic to cultured neurons. Also provided is a method for growing cells comprising: growing a quantity of cells in a suitable growth media comprising an effective amount of a peptide comprising a lysosomal targeting motif and a domain specific for the derlin-binding region of superoxide dismutase 1.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Oxidized SOD1 accelerates cellular senescence in stem cells

[0002] PRIOR APPLICATION INFORMATION

[0003] The instant application claims the benefit of US Provisional Patent Application 63 / 502,201 , filed May 15, 2023 and entitled “Oxidized SOD1 accelerates cellular senescence in neural stem cells”, the entire contents of which are incorporated herein by reference for all purposes.

[0004] BACKGROUND OF THE INVENTION

[0005] Adult neural stem cells (NSCs) are present in the subgranular zone of the dentate gyrus, the subventricular zone of the lateral ventricles [1 , 2] and the ependymal layer in the spinal cord [3-5]. These cells are typically maintained in a state of quiescence but can be activated to enter the cell cycle [6]. Emerging observations suggest that proteostasis plays an important role in maintaining NSC quiescence [7], Clearance of protein aggregates activates NSCs [8-10]. Upon aging, NSCs undergo proliferative declines and cellular senescence due to accumulation of protein aggregates

[0011] . To counteract these effects, stimulation of lysosomal activity to enhance degradation of protein aggregates rejuvenates aged NSCs

[0012] , Superoxide dismutase 1 (SOD1 ) is an antioxidant responsible for neutralizing supercharged oxygen radicals in the cell. It exists predominantly in cytoplasm, although a small portion of SOD1 monomers are present in the mitochondrial inner membrane space to scavenge superoxide ions generated from the mitochondrial respiration chain. Deficiency in SOD1 leads to accumulation of oxidants in the cell

[0013] and accelerates age-associated behavioral abnormalities

[0014] , Interestingly, SOD1 is susceptible to oxidative modifications, and can even be oxidized by hydrogen peroxide

[0015] , its own catalytic reaction product. Mutations in the human SOD1 gene increase its susceptibility to oxidation and are a cause of familial amyotrophic lateral sclerosis (ALS), an age-related neurodegenerative disease [16- 19]. The cysteine 111 of human SOD1 (hSOD1) is particularly susceptible to oxidation [15, 17], Oxidatively modified SOD1 adopts a misfolded conformation that exposes its hydrophobic sequences to interact covalently with the exposed hydrophobic patches of other misfolded SOD1 in its vicinity. Such oligomers even offer covalent attachment to other native proteins and form high molecular weight aggregates [15, 17], As such, oxidation of SOD1 triggers aberrant misfolding and protein aggregation. Meanwhile, oxidized hSOD1 tends to localize to mitochondrial membranes and causes mitochondrial dysfunction [20, 21], Oxidization of SOD1 has therefore been suggested to play a role in aging and age-related diseases [22, 23]. The present study aims to examine the role of oxidized human SOD1 in cellular senescence of NSCs. Here we report that oxidized SOD1 accumulates in NSCs expressing human SOD1 after repeated passages in culture. With accumulation of oxidized human SOD1 , NSCs undergo early entrance into replicative senescence. Selective removal of the oxidized SOD1 remarkably reduces biomarkers of cellular senescence and increases proliferation and sternness of NSCs. Extracellular vesicles (EVs) isolated from senescent NSCs contain high levels of oxidized human SOD1 and induce senescence of fresh NSCs. Neutralization of oxidized human SOD1 on EVs with an interference peptide specific for oxidized SOD1 blocks the EVs-induced senescence of NSCs. Our data support that oxidized SOD1 is a causing factor of cellular senescence of NSCs. Selective removal of oxidized SOD1 is a strategy to rejuvenate NSCs.

[0006] Mesenchymal stem / stromal cells (MSCs), a pivotal component of the stem cell family, are multipotent cells capable of differentiating into mesodermal cell types, including osteogenic, chondrogenic, and adipogenic lineages

[0047] , These cells, found in the connective tissue of most adult organs, play a critical role in tissue repair and regeneration

[0048] . MSCs are characterized by their plastic adherence, specific cell surface marker expression, and the ability to differentiate into various tissue cells such as fat, bone, cartilage, muscle, tendons, ligaments, nerves, liver, myocardium, and endothelium

[0049] . They can be isolated from various sources, including bone marrow, placenta, adipose tissue, dental pulp, endometrium, menstrual blood, peripheral blood, salivary glands, skin, synovial fluid, and various perinatal tissues

[0050] .

[0007] Human bone marrow-derived mesenchymal stem cells (hBMSCs) have emerged as pivotal players in regenerative medicine, attributed to their multipotency, anti-inflammatory, and immunomodulatory capabilities [51 , 52], Their ability to differentiate into a diverse array of cell types — including bone, cartilage, fat, tendon, muscle, and neural cells — under specific in vitro and in vivo conditions positions them as prime candidates for addressing age and disease-related cellular, tissue, and organ damage, as well as for immunomodulatory applications in managing immune rejection and autoimmune diseases [53, 54], The therapeutic potential of hBMSCs hinges on their capacity for direct differentiation, enhancement of endogenous repair mechanisms, and modulation of inflammatory responses, underpinning their role in tissue repair and regeneration.

[0008] However, the practical application of hBMSCs in clinical settings depends on overcoming significant challenges related to their ex vivo expansion, including the need for large quantities of high-quality cells. This requirement is critical for ensuring successful engraftment, structural organization, and cellular differentiation, which are essential for integrating BMSCs into target tissues and initiating repair processes. Yet, a significant obstacle in the expansion of human BMSCs (hBMSCs) in vitro is their progressive decline in early progenitor characteristics

[0055] and an increase in cellular senescence

[0056] , which compromises their regenerative and immunomodulatory functions. The mechanisms underlying these changes remain elusive, presenting technical challenges in preventing senescence and maintaining the hBMSCs' functional capabilities.

[0009] Among the various techniques to enhance the proliferation of hBMSCs, the modulation of oxygen tension emerges as a critical strategy [57, 58]. Conventionally, hBMSCs are expanded for therapeutic applications under atmospheric oxygen levels (approximately 21% O2), a condition that predisposes cells to pro-oxidative stress. It has been demonstrated that culturing hBMSCs under lower, physiologically relevant oxygen concentrations can markedly extend their lifespan by mitigating oxidative stress, reducing DNA damage, preventing telomere shortening, and decreasing the incidence of chromosomal aberrations

[0059] . Such hypoxic conditions also inhibit phenotypic alterations and slow the decline in proliferation during culture, primarily through the reduction of reactive oxygen species (ROS) formation

[0060] , thus minimizing molecular damage and promoting cell viability.

[0010] SUMMARY OF THE INVENTION

[0011] According to an aspect of the invention, there is provided a method for growing cells comprising: growing a quantity of cells in a suitable growth media comprising an effective amount of a peptide comprising a lysosomal targeting motif and a domain specific for the derlin- binding region of superoxide dismutase 1 .

[0012] The peptide may be arranged or formulated for penetration or entry into the quantity of cells, for example, by further comprising a cell-penetration domain.

[0013] The cell penetration domain may be selected from the group consisting of: cellpenetration domain of Tat peptide, penetratin domain of the antennapedia, TAT(48-60), R8 and R9.

[0014] The lysosomal targeting motif may be the chaperone-mediated autophagy targeting motif (CTM).

[0015] The cells may be stem cells, for example, human stem cells.

[0016] The human stem cells may be human neural stem cells or human mesenchymal stem cells.

[0017] Preferably, the cells are grown in vitro.

[0018] In some embodiments of the invention, extracellular vesicles are recovered from the growing human stem cells.

[0019] Extracellular vesicles, also known as exosomes, are 70 - 150 nm vesicles secreted by cells. They carry various biological molecules, including proteins, lipids, and nucleic acids, which can be transferred to recipient cells, influencing their functions. In recent years, exosomes have attracted significant attention due to their potential applications in various fields, such as medicine, diagnostics, and therapeutics. What we have found is that EVs prepared from senescent NSCs contain oxidized SOD1 and are toxic to cells. Therefore, it is necessary to remove oxidized SOD1 from EVs so that their potential toxicity can be mitigated. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Fig. 1. Cellular senescence of NSCs expressing hSOD1 after repeated passages in culture. A. Sequences of CT4 and mCT4 peptides. B. Number of NSCs carrying WT hSOD1 after each passage. CT4 at 5 pM once every other day increased the number of NSCs at every passage. C. CT4 doubled the size of neurospheres at P5. D. Levels of misfolded SOD1 in NSCsWT. Western blot with an antibody was used to hSOD1. The differences between CT4 and mCT4-treated cells represents misfolded SOD1. E. A modified immunosorbent assay was used to detect the thiol-disulfide status of hSOD1 in NSCsWTtreated with CT4 or mCT4 at P5. F. Western blot detection of misfolded SOD1 with the A5C3 antibody. G. A modified immunosorbent assay was used to detect the thiol-disulfide status of the hSOD1 in NSCsWTtreated with CT4 or mCT4 at P3 and P5. The thiol content was normalized to total hSOD1 , measured using a commercial ELISA kit. For C and F, Two-tailed t-test was performed; For D, E and G, Two-way ANOVA followed by Sidak’s multiple comparisons test was performed. *P < 0.05; **P < 0.01. All analysis was done in triplicate from three independent cultures of each strain.

[0021] Fig. 2. NSCs undergo early entrance into replicative senescence in the presence of misfolded hSOD1. A. WT and G93A over-expression in NSCs results in diminished proliferation. Cell proliferation was visualized by immunostaining with Ki67 (Green) and neural stem cell marker SOX2 (Red) in P5 NSCsWT. Scale bar: 20pm. One-way ANOVA followed by Bonferroni’s Multiple Comparison Post-Test. B. P5 NSCsWTwere treated with mCT4 and CT4, and Cell proliferation was visualized by immunostaining with Ki67 (Green) and neural stem cell marker SOX2 (Red) 24 hours after. Scale bar: 20pm. Student’s t-test. C. Representative immunoblot of P53 expression of difference passage of NSCsWTand NSCsG93A; Quantitative data of P53 expression Total protein generated by stain-free visualization was used to ensure equivalent loading. Two-way ANOVA followed by Sidak’s multiple comparisons test was performed. All analysis was done in triplicate from three independent cultures.

[0022] Fig. 3. Extracellular vesicles from senescent NSCs contained misfolded hSOD1 A. Affinity binding assay showed that GST-tagged CT4 binds with misfolded SOD1 that isolated from P3 and P5 of NSCsWTand NSCsG93A. Blots were probed with an antibody that recognizes hSOD1. Input: total SOD1 in each lysate. B. EM analysis of whole-mount EVs. Morphology is observed by negative staining. C. A modified immunosorbent assay was used to detect the thiol-disulfide status of the SOD1 in EVsWTand EVsG93Afrom indicated passages of NSCs. The thiol content was normalized to total hSOD1 , measured using a commercial ELISA kit. Two-way ANOVA followed by Sidak’s multiple comparisons test was performed, n = 6 from 3 separate cultures, Bars represent mean ± SD. D. SOD1 expression in EVs from P5 NSCsWTand NSCsG93Awas analyzed by nonreducing (- 2-Mercaptoethanol / -i-iodoacetamide) SDS-PAGE by hSOD1 (Left) and A5C3(misfolded SOD1 , Right) immunoblot. Total protein generated by stain-free visualization was used to ensure equivalent loading. The experiment was done in triplicate from three independent cultures.

[0023] Fig. 4. Internalization Exogenous EVs from senescence NSC induce aging-like phenotypes. A. Internalization of exogenous EVs that contain pathogenic hSOD1. Representative immunofluorescence staining of misfolded SOD1 (B8H10, Green) and hSOD1 (blue) after treatment with EVsWTand EVsG93Afrom P5 of NSCs. EVs were labeled with Texas Red. Scale bar: 2pm. B. Immunofluorescence staining of P3 NSCsWTwith HMGB1 (Green) and Nestin (Red) after treatment with P5 EVsWTand EVsG93A(Left panel). Senescent NSCs were stained blue through the cleavage of the chromogenic substrate X-Gal that was catalyzed by SA-p-gal (Right panel). C. The translocation of HMGB1 from the nucleus to the cytosol in the P3 recipient NSCsWTwas summarized in the bar graph. D. SA-p-gal positive rate was quantified in the bar graph. For C and D, one-way ANOVA followed by Bonferroni’s Multiple Comparison Post-Test was performed. The experiment was done in triplicate from three independent cultures.

[0024] Fig. 5. Exogenous EVs from senescence NSC activate the p53 pathway. A. P5 EVsWTand EVsG93Atreatment results in diminished proliferation in P3 NSCsWT. Cell proliferation was visualized by immunostaining with Ki67 (Red) and Nestin (Green). Scale bar: 20pm. Two-way ANOVA followed by Sidak’s multiple comparisons test was performed. B. Representative immunoblot and quantitative data of P16 and C. P53 expression. One-way ANOVA followed by Bonferroni’s Multiple Comparison Post-Test was perform. D. GST-tagged CT4 epitope of Derlin-1 precipitated EVs that expressed misfolded SOD1. Cell proliferation was visualized by immunostaining with Ki67 (Red) and Nestin (Green). For quantitative data of Ki67+ cell count, Two-tailed student’s t-test was performed. The experiment was done in triplicate from three independent cultures.

[0025] Fig. 6. Blocking senescence inducing SOD1 reduces aggregation and mitigates neurotoxicity. A. Representative immunoblot of detergent-insoluble and soluble fractions of cells with CT4 pre-treatment. Blots were probed with anti-hSOD1. Total protein generated by stain-free visualization was used to ensure equivalent loading. B. Quantitative data of detergent-insoluble and soluble fractions. Two-way ANOVA followed by Sidak’s multiple comparisons test was performed. C. Neurontoxicity was visualized by immunostaining with misfolded SOD1 (B8H10, Red) and MAP-2 (Green). D. Quantitative data of MAP-2+ cell count and E. LDH release. For Fig. D and E, one-way ANOVA followed by Bonferroni’s Multiple Comparison Post-Test was performed. The experiment was done in triplicate from three independent cultures.

[0026] Fig. 7. Misfolded hSOD1 knockdown enhanced hBMSC growth and proliferation. A) Morphology of hBMSCs expanded at P7 for 72 h. Representative images are shown. The images were captured at 10X magnification with a scale bar of 200 pm. B) Cell count of hBMSC at P7. C) Total protein per cell. Data are presented as the mean ± SD. Two-way ANOVA followed by Sidak’s multiple comparisons test was performed. All analysis was done in triplicate from three independent cultures.

[0027] Fig. 8. Misfolded hSOD1 knockdown promoted hBMSCs proliferation. A) Under normoxic conditions, growth curves for hBMSCs were plotted. B) Population doubling time (PDT) was reduced by misfolded hSOD1 knockdown. Analysis was done in triplicate from three independent cultures. Data are presented as the mean ± SD. Two-way ANOVA followed by Sidak’s multiple comparisons test was performed.

[0028] Fig. 9. Misfolded hSOD1 knockdown did not affect hBMSC differentiation. A) Alizarin red S staining of calcium deposits. B) OD values of Alizarin red S staining. C) Oil Red O staining for lipid droplet formation. D) OD values of Oil Red O staining. Scale bar = 20 pm. Data are shown as the means ± SD. Students' t-tests were used, and analysis was done in triplicate from three independent cultures.

[0029] Fig. 10. Oxidization and misfolding of hSOD1 in the extended culture of hBMSCs. A) CT4-GST pulls down misfolded hSOD1 from P7 and P15 hBMSCs. B) Quantitative analysis of misfolded hSOD1 , shown as a proportion of total hSOD1 content. C) Representative blot of MalPEG conjugation assay. D) Quantitative analysis of the proportion of oxidized hSOD1 in P7 hBMSCs. E) Quantitative analysis of the proportion of oxidized hSOD1 in P15 hBMSCs. The data are shown as the means ± SD. Students' t-tests were used, and analysis was done in triplicate from three independent cultures.

[0030] Fig. 11. EVs from the extended culture of hBMSCs induced hSOD1 oxidation and inhibited hBMSCs proliferation. A) P15 hBMSCs-derived EVs contain misfolded hSOD1. One-way ANOVA followed by Bonferroni's Multiple Comparison Post-Test was performed. B) Representative blot of hSOD1 oxidation induced by P15 hBMSCs-derived EVs. C) Quantitative analysis of recipient hBMSCs oxidized hSOD1 level, shown as a proportion of total hSOD1 content. Student's t-test. D) Morphology of hBMSCs expanded at P7, and representative images are shown. E) Cell counts were performed microscopically. Two-way ANOVA followed by Sidak's multiple comparisons test was performed. The data are shown as the means ± SD, and analysis was done in triplicate from three independent cultures.

[0031] Fig. 12. Similar knockdown efficiency of CT4L and CT4S. A). Representative images of WT hSOD1 overexpressing CHO that treat with 40 pM CT4L or CT4S. Bar = 50 pm B). Quantitative analysis of GFP intensity of CT4L and CT4S treatment at 40, 20, and 10 pM. C). Quantitative analysis of cell viability of CT4L and CT4S treatment at 40, 20, and 10 pM. D). GFP intensity changes over 4 h in CT4L and CT4S-treated cells at 20 pM. * P<0.05 vs control, ** P<0.01 vs control. All experiments were performed in triplicate, All data are expressed as the mean. ± standard deviation. For B and C, one-way ANOVA was performed; for D, two-way ANOVA was performed.

[0032] DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0033] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned hereunder are incorporated herein by reference.

[0034] As individuals age, adult neural stem cells (NSCs) undergo cellular senescence. Human SOD1 is known to be susceptible to oxidization in oxidative stress. Once oxidized, it undergoes aberrant misfolding and gains toxic properties that are associated with age-related neurodegenerative disorders. The present study aims to examine the role of oxidized human SOD1 (hSOD1) in cellular senescence of NSCs. Here we show that oxidized hSOD1 accumulates in NSCs expressing hSOD1 undergo repeated passages. During this process, the NSCs exhibit an increasing expression of biomarkers of cellular senescence including upregulation of P53 and SA-p-Gal, and cytoplasmic translocation of HMGB1. It is well known that NSCs, especially human NSCs, undergo cellular senescence characterized by irreversible proliferation arrest and loss of sternness

[0030] . A growing body of evidence points toward reactive oxygen species (ROS) as one of the primary determinants of cellular senescence of NSCs. While compelling correlative data have been generated to support the oxidative stress theory, a direct cause-and-effect relationship between the accumulation of oxidation-mediated damage and cellular senescence of NSCs has not been firmly established [23, 31]. Here we report that mouse NSCs expressing the full length human SOD1 increasingly express biomarkers of cellular senescence with repeated passages in vitro. In this process, levels of misfolded hSOD1 in the NSCs increase with the increased number of passages. Selective removal of misfolded SOD1 from NSCs remarkably increases proliferation and sternness of NSCs. Our study also reveals that extracellular vesicles (EVs) derived from senescent NSCs expressing the wild type hSOD1 contain high level of misfolded SOD1 that is oxidized and toxic to cultured neurons. Application of the exogenous EVs originating from senescent NSCs has been found to accelerate the senescence in healthy NSCs. Removal of senescence inducing EVs using a misfolded SOD1 binding peptide abolishes senescence-inducing activity and promotes proliferation of NSCs. Our data indicate that oxidized hSOD1 is a causal factor in cellular senescence of NSCs. Selective removal of oxidized SOD1 is an effective way to improve the quality and production of human NSCs for cell-based therapies.

[0035] Aging not only leads to a disrupted cell metabolism, but also results in the intracellular accumulation of misfolded and aggregated proteins. Protein misfolding is both a cause and a consequence of increased cellular stress and has been observed in the nervous tissues of patients affected by a variety of age-related disorders, such as Alzheimer’s disease, and ALS

[0032] , The ability of NSCs to self-renew and differentiate into multiple neural lineages makes them indispensable in maintaining a multipotent reservoir and generate differentiated cells. A recent study shows that self-association and subsequent deposition of the misfolded protein aggregates are largely present in the resting NSCs, and the accumulation of protein aggregates contained within lysosomes in healthy young adult NSCs play a physiological role since they are required for NSCs mobilization and activation [6]. Young stem cells are relatively robust to handle misfolded protein through high levels of the ATP-dependent TRiC / CCT Chaperonin

[0033] . In aged NSCs, the ability to reactivate (i.e., re-entry to cell cycle) is limited due to fewer lysosomes being available to fuse with autophagosomes for autophagy to remove toxic proteins [6]. Defects of lysosomes and accumulation of protein aggregates also display delayed proteotoxicity to differentiated cells derived from aged NSCs. Manipulation of autophagy to enhance aggregate clearance has been shown to rejuvenate aged NSCs

[0012] , Given that NSCs can be isolated from brains of presymptomatic mice but not symptomatic SOD1 G93A mice, which are known to carry aggregate-prone SOD1

[0034] , we would speculate that oxidized SOD1 contributes to the progression of aging by impairing NSCs proteostasis.

[0036] ALS-linked hSOD1 variants have been shown to induce prion-like transmission

[0035] . Misfolded wild-type hSOD1 is detected in the cerebrospinal fluid (CSF) from patients with sporadic ALS

[0036] , and the CSF samples exhibit significant toxicity toward NSC-34 cells. However, it remains to be tested whether wild-type hSOD1 secreted in its oxidized form from aged NSCs triggers further misfolding and aggregation of proteins in neighboring cells. Thioldisulfide status facilitates the protein misfolding and play a regulatory role in SODI ’s gain of toxic function

[0037] , Human SOD1 has four cysteine residues (Cys6, Cys57, Cys111 , and Cys146). An internal disulfide bond exists between Cys57 and Cys146, which contributes to the high stability of the SOD1 protein, while cysteines at positions 6 and 111 are free, and can be reversibly oxidized to a sulfenic acid (Cys-SOH) by low concentrations of hydrogen peroxide or irreversibly to sulfinic (Cys-SOgH) I sulfonic (Cys-SOsH) acids by high concentrations of hydrogen peroxide [38-40]. Studies show that hSOD1 proteins are readily susceptible to oxidation at the free cysteine residues [16, 18, 41 , 42], Our data show that oxidation of hSOD1 occurs in NSCs after repeated passages in culture. Oxidized SOD1 inevitably undergoes aberrant misfolding

[0017] and is not readily degraded through common protein degradation pathways. As a result, accumulation of oxidized and misfolded SOD1 is detected in aging and age-related neurodegenerative diseases [22, 43]. Selective removal of misfolded SOD1 is therefore a strategy to rejuvenate NSCs.

[0037] Extracellular vesicles serve as a major element in communicating and coordinating the function of adult neurogenic niches

[0044] , Protein aggregates can be released via exocytosis in a form of extracellular vesicles for toxic protein disposal, which is a hallmark for cells with low lysosome number or lysosomal activity

[0045] . Exosome-based therapies are an emerging field in medicine and hold potential to revolutionize the treatment of various diseases. Our data show that EVs from aged NSCs carrying the hSOD1 gene contain considerable levels of oxidized SOD1 and are senescence-inducing and toxic to NSCs and neurons. It is therefore necessary to include the level of oxidized SOD1 in the quality control of EV preparation. A previous study has shown that EVs enter target cells but lack association with lysosomal- associated membrane protein 1 (LAMP1 )

[0046] , implying that low degradation efficiency in aged NSCs is a consequence of not only the declined lysosomal activity but also the decreased binding with lysosomes for quick clearance.

[0038] Together, the present study provides new insights into cellular senescence of NSCs and demonstrates that targeting oxidized SOD1 is an effective way to rejuvenate NSCs and to improve clinical outcome of exosome-based therapies.

[0039] According to an aspect of the invention, there is provided a method for growing cells comprising: growing a quantity of cells in a suitable growth media comprising an effective amount of a peptide comprising a lysosomal targeting motif and a domain specific for the derlin- binding region of superoxide dismutase 1 .

[0040] In some embodiments of the invention, the peptide is arranged or formulated for penetration or entry into the quantity of cells.

[0041] In some embodiments of the invention, the peptide is arranged for penetration or entry into the quantity of cells by further comprising a cell-penetration domain. The cell penetration domain may be the cell-penetration domain of Tat peptide, the penetratin domain of the antennapedia or a synthetic peptide such as for example but by no means limited to TAT(48- 60) or a polyarginine peptide such as R8 or R9.

[0042] In some embodiments of the invention, the lysosomal targeting motif is the chaperone- mediated autophagy targeting motif (CTM).

[0043] As will be appreciated by those of skill in the art, the derlin-binding region (DBR) of SOD1 is exposed only when SOD1 is misfolded.

[0044] In some embodiments of the invention, the cells are stem cells, for example, human stem cells, for example neural stem cells or mesenchymal stem cells.

[0045] As will be appreciated by one of skill in the art, the cell growth media will be selected according to the type of cell being grown. As such, a “suitable growth media” or a “suitable culture media” or a “suitable growth culture media” will be readily apparent to one of skill in the art and represents a growth media that is known to support growth of the cells of interest, that is, the cells being grown. For example, NSCs are grown in Complete StemPro NSC media containing basic fibroblast growth factor (bFGF) (20 ng / ml) and human epidermal growth factor (hEGF) (20 ng / ml). However, NSCs can grow in other media such as DMEM with growth factors as well.

[0046] In some embodiments of the invention, there is provided a method for growing cells comprising: growing a quantity of cells in a suitable growth media; transferring the growing cells to fresh growth media comprising an effective amount of a peptide comprising a lysosomal targeting motif and a domain specific for the derlin-binding region of superoxide dismutase 1 .

[0047] In some embodiments of the invention, the cells are subcultured at a ratio of about 1 to about 3, wherein “about” means the base value plus or minus 10%.

[0048] It is noted that one of skill in the art can readily determine when the cells should be subcultured, which may be based on for example the specific growth culture media used and / or the confluence of the cells in the media and / or the growth rate of the cells. For example, as discussed herein, the cells may be subcultured every 2-3 days.

[0049] As discussed herein, the above-described methods for growing cells are an improvement over the prior art in that proliferation and sternness of the cells grown according to the methods described herein are improved or increased compared to cells grown under similar conditions except for the presence of the peptide. As discussed herein, the peptide significantly increased the number and size of the neurospheres compared to untreated control cells.

[0050] A used herein, an “effective amount” of the peptide is an amount that is sufficient to selectively direct misfolded SOD1 to lysosome for degradation, for example, in some embodiments, through the chaperone-mediated autophagy pathway. As discussed herein, this knockdown of misfolded SOD1 rejuvenates NSCs as evidenced by their increased proliferation and sternness. Meanwhile, exosomes prepared from senescent NSCs accelerate aging in NSCs and are toxic to neurons. Removal of misfolded SOD1 from the exosomes abolishes their detrimental effects. Effective dosages are between about 2.5 to about 10 mM.

[0051] As discussed herein, the method helps increase the production and improve the quality of SCs and extracellular vesicles.

[0052] Some examples of what stem cells are used for include but are by no means limited to:

[0053] 1. Regenerative medicine: Stem cells can be used to repair or replace damaged tissues and organs in the body, potentially offering treatments for conditions like heart disease, diabetes, spinal cord injuries, and neurodegenerative disorders such as Parkinson's disease and Alzheimer's disease.

[0054] 2. Hematopoietic stem cell transplantation: Hematopoietic stem cells (HSCs), found in bone marrow, peripheral blood, and umbilical cord blood, can give rise to all types of blood cells. HSC transplantation is a well-established and FDA-approved therapy for treating blood disorders like leukemia, lymphoma, multiple myeloma, and certain types of anemia.

[0055] 3. Drug discovery and testing: Stem cells can be used as model systems for screening and testing potential therapeutic compounds for their efficacy and safety in treating various diseases.

[0056] 4. Disease modeling: Stem cells can be generated from patient-derived induced pluripotent stem cells (iPSCs), allowing researchers to study the molecular and cellular mechanisms of various diseases in a laboratory setting.

[0057] 5. Developmental biology research: Stem cells provide an excellent model for studying early development and the molecular mechanisms regulating cell differentiation and maturation.

[0058] 6. Gene therapy: Stem cells can be used as vehicles for gene delivery to target tissues or organs, potentially treating genetic disorders.

[0059] 7. Tissue engineering: Stem cells can be used in combination with biomaterials to generate functional tissue replacements for damaged or lost tissues, such as cartilage, skin, or blood vessels. hBMSCs exhibit cellular senescence characterized by a decline in their proliferation and inherent stem cell properties after extended periods in culture

[0066] . Increasing evidence suggests that ROS plays a crucial role in driving the senescence of hBMSCs

[0067] , In this study, the halt in cell proliferation observed in hBMSCs following repeated passages in vitro was alleviated by CT4. This treatment, aimed at targeting the misfolded form of hSOD1 for degradation, mitigated the arrest in proliferation and was associated with reduced levels of oxidized hSOD1. Our findings indicate a potential interplay between the misfolding and oxidation of SOD1 , where each process may exacerbate the other and promote proteotoxicity. We further demonstrated that these proteotoxic, post-translationally modified forms of hSOD1 are present in EVs, potentially enabling the transmission of these modifications to native hSOD1 via a prion-like mechanism. Remarkably, the selective removal of misfolded hSOD1 from recipient cells effectively blocked the detrimental impact of EV transmission, restoring proliferative capacity.

[0060] Our observations have identified the presence of human SOD1 (hSOD1) within EVs, which are released by a vast array of cell types, including those undergoing pathological changes [35, 65, 71 , 72], EVs play a critical role in intercellular communication, facilitating the transfer of diverse biomolecules such as nucleic acids, proteins, and metabolites to recipient cells. This process of cargo selection within EVs is highly selective and orchestrated by intricate sorting mechanisms

[0073] . Our study has elucidated that hBMSCs expel proteotoxic hSOD1 via EVs, which diminishes the proliferation capabilities of recipient hBMSCs. This process potentially alters the fundamental biology of hBMSCs, particularly their cell cycle dynamics.

[0061] The presence of proteotoxic hSOD1 necessitates a re-evaluation of the criteria for clinical utilization of hBMSCs, underlining the argument that effective therapeutic outcomes depend not just on the number of cells transplanted but, critically, on their intrinsic quality.

[0062] These findings indicate that hSOD1 proteotoxicity plays a causative role in the reduction of hBMSCs' proliferation, highlighting a novel target for interventions aimed at mitigating the limitation of cell-based therapy.

[0063] Finally, we conducted imaging and quantified GFP intensity in hSOD1WT-overpexressed CHO cells treated with CT4L and CT4S peptides. The observed outcomes align with expectations based on previous findings that the peptide treatment enhances lysosomal targeting, thereby facilitating more efficient hSOD1 degradation and clearance. As shown in Fig. 12A, evidence of GFP aggregation was noted, characterized by a bright green signal in control group, indicating hSOD1WTmisfolding. Diffusely distributed cytosolic hSOD1WTwere observed in both treatment groups. Moreover, GFP intensity was markedly reduced in cells treated with CT4L or CT4S (40 pM) after 4 hours of treatment. However, the CT4L 40 pM group exhibited signs of early apoptosis, such as increased cell rounding, shrinkage, and cytoplasm condensation (Fig. 12A). Quantitative analysis of GFP intensity revealed a significant decrease of 46 ± 17% at 4 hours post-application of 20 pM CT4L, with the CT4S- treated cells showing a similar reduction of 48 ± 14%. A more pronounced decrease of 82 ± 13% was observed at 4 hours after treating with 40 pM CT4L, whereas the reduction in the CT4S-treated cells was at 46 ± 17% compared to control (Fig. 12B). Subsequent cell viability assessments, as illustrated in Fig. 12C, revealed that 40 pM CT4L significantly affected cell viability, consistent with the phase-contrast observation. Thereafter, continuous GFP monitoring was then done at a 20 pM dosage, selected due to its negligible impact on cell viability. The alterations in GFP fluorescence intensity were plotted for the two treatment and control groups. The performance of CT4S was found to be on par with that of CT4L, suggesting that substituting the CTM domain with the KFERQ motif alone is sufficient to achieve a similar extent of knockdown efficiency.

[0064] Peptide. CT4L (YGRKKRRQRRR-FLYRWLPSRRGG-KFERQKILDQRFFE, SEQ ID NO:1 ) and CT4S (KFERQ-FLYRWLPSRRGG-YGRKKRRQRRR, SEQ ID NO:2) peptides were obtained from the Peptide Synthesis and Purification Core Facility at the University of British Columbia.

[0065] Plasmids. Plasmids pF141 pAcGFPI S0D1 WT (RRID:Addgene_26402) was a gift from Dr. Elizabeth Fisher. Transfections of hSOD1WTwere performed using FuGENE 6 transfection reagent (Promega, Madison, Wl) according to the manufacturer’s instructions.

[0066] Cell culture and treatment. Cells stably transfected with hSOD1WTwere maintained in phenol red-free Dulbecco’s modified Eagle’s medium (DMEM, 31053028, Life Technologies) supplemented with 10% fetal bovine serum (FBS, 12484028, Life Technologies) and G418 at 1 mg / mL based on the kill curve. Cultures were incubated in a 5% CO2 atmosphere at 37 °C. To induce misfolding of endogenous hSOD1 , serum starvation was initiated 24 h before administering the peptides, which were then bath applied to the media. At specified time points, the conditioned media were collected, and viability of cells in each group treated with varying amounts of peptides were examined using the WST-1 assay. The conditioned media were subjected to sequential centrifugation steps to eliminate cells, cellular membranes, and debris, then the fluorescence intensity of GFP was measured using excitation and emission wavelengths of 480 nm and 520 nm with a Synergy Mx multi-mode microplate reader (BioTek).

[0067] The invention will now be further explained and / or elucidated by way of examples; however, the invention is not necessarily limited to or by the examples.

[0068] EXAMPLE 1. Oxidized SOD1 accumulates in NSCs expressing hSOD1 after repeated passages in culture

[0069] Previously we reported that oxidation of hSOD1 occurred at its cysteine 11 1 residue [15, 17], Once oxidized, hSOD1 undergoes aberrant misfolding. We first determined the expression of misfolded SOD1 in NSCs after repeated passages, a model of NSC senescence. NSCs were prepared from transgenic mice expressing the full length of human wild type SOD1 (NSCsWT). The cells were maintained in Complete StemPro NSC media to form neurospheres, and then subcultured at a 1 :3 ratio every 2-3 days. Cells from passage 3 (P3) were used for experiments. CT4 fusion peptide was applied to NSCs for selective knockdown of misfolded SOD1 , while mCT4, a mutant form of CT4, was used as control. As shown in Fig. 1 B, NSCsWTtreated with the control peptide mCT4 kept proliferating after each passage until P7 and the proliferation stopped from P8. Most of the cells died at P10. Supplement of CT4 at 5 pM in culture medium once every other day remarkably increased proliferation and viability of NSCsWTat all passages compared to those treated with mCT4. Noticeably, CT4 doubled the number of NSCs at P7 and P8. Meanwhile, the number of neurospheres started to decline at P3 and became significantly reduced at P5. Treatment with CT4 significantly increased the number and size of neurospheres, an indicator of sternness of NSCs. At P5, the neurospheres treated with CT4 were twice larger than those treated with mCT4 (Fig. 1C).

[0070] From P3 and P5, there was a general increase in the expression of total hSOD1. Noticeably, in passage 5 cells, treatment with CT4 resulted in lower levels of hSOD1 expression compared to mCT4 treated cells. These findings were validated by using a western blot assay, which detected hSOD1 using an antibody (Abeam AB52950) specific to human SOD1 (Fig. 1 D), and an ELISA assay utilizing a Cu / ZnSOD Human Matched Antibody Pair (Thermo, # BMS222MST) (Fig. 1 E). Considering the CT4 specific effectiveness in degrading misfolded SOD1 protein, it can be inferred that there was a certain level of misfolded protein accumulation within the stem cells by P5. Therefore, we further conducted a western blot analysis using a conformation specific SOD1 antibody A5C3 on P5 NSCsWT. As expected, accumulation of misfolded SOD1 was found in P5 NSCsWT, which can be reduced by CT4 significantly (Fig. 1 F). Misfolding of SOD1 can lead to the formation of unstable intermediates that are more prone to oxidation, while human SOD1 cysteine residues, which are particularly susceptible to oxidation, results in a change in thiol redox state. To test the level of oxidized SOD1 , we aliquoted the cell lysates from P3 and P5 NSCsWTand incubated in aerobic humidity chamber at 4°C to allow air oxidation. Second set of samples were kept in anaerobic humidity chamber at 4°C. These two sets of lysates were then transferred to the hSOD1 antibody-coated plate to allow hSOD1 immobilization. Maleimide-activated HRP was used to determine the thiol content of the captured SOD1 thereafter. Signal from this modified ELISA represents the available maleimide group that can react with sulfhydryl containing molecules. The A-SH was calculated by comparing the percentage change in OD450 between the aerobic and anaerobic samples. The amount of oxidized SOD1 is inversely correlated with A-SH. As shown in Fig. 1G, there was a significant reduction in A-SH between P3 and P5 NSCsWTtreated the mCT4. Targeting misfolded SOD1 with CT4 significantly prevented the thiol oxidation at P5.

[0071] EXAMPLE 2. NSCsWTundergo early entrance into replicative senescence in the presence of misfolded hSOD1

[0072] We then measured the proliferation and self-renewal of NSCs immunologically with antibodies to Ki67 and SOX2 at P5, which was around 2 weeks of culture in vitro. As shown in Fig. 2A, about 58% of non-transgenic NSCs (NSCs_ / ) were positive for Ki67 at P5. There were only 30% of cells positive for Ki67 in the NSCsWT, a significant drop of 51.8% as compared to the NSCs / _. As a positive control, we included NSCs expressing the G93A mutation of hSOD1 (NSCsG93A, obtained from G93A-hSOD1 mouse E14 embryos). In the hSOD1G93Agroup, cells positive for Ki67 further reduced to 12.4% at P5. In NSCsWTat P5, application of CT4 at 5 pM once every other day to remove misfolded SOD1 doubled the number of Ki67-positive cells and significantly increased Sox2-positive cells (Fig. 2B). We further analyzed the expression of the oncoprotein p53, a marker of cellular senescence, in whole-cell lysates of NSCsWTfrom passages 1 , 3 and 5. While NSCs / _didn’t express P53 throughout the 5 passages, NSCsWTand NSCsG93Ashowed upregulation of P53 after each passage. Specifically, in the NSCsWTgroup, P53 increased by 4.3-fold in P3 and 7.3 fold in P5 compared to P1. In the NSCsG93A, levels of P53 increased by 6.8-fold in P3 and nearly 12- fold in P5 compared to P1 (Fig. 2C).

[0073] EXAMPLE 3. EVs from senescent NSCs contained misfolded hSOD1

[0074] Pathogenic hSOD1 is known to propagate through protein secretion and EVs

[0029] . To determine if senescent NSCs secrete misfolded SOD1 , we prepared EVs from culture media of mouse NSCs carrying hSOD 1WT(EVsWT) or hSOD1G93A(EVsG93A) at passages 1 , 3 and 5 respectively. Using a GST-CT4 pulldown assay, a weak band of misfolded SOD1 was detected in NSCsWTat P3. Levels of misfolded SOD1 in NSCsWTincreased significantly at P5 (Fig. 3A). At passage 1 , there was no detectable misfolded SOD1 in the NSCsWT. Electron microscopy of whole-mount EVs revealed no significant morphological difference between EVsWTand EVsG93Aat P5. The EVs had a diameter ranging between 50-150 nm (Fig. 2B). To test if misfolded SOD1 in EVs was oxidized, we aliquoted the EVs lysates and incubated them in aerobic or anaerobic chamber overnight. The lysates were then added to a plate coated with an antibody to hSOD1 to immobilize hSOD1. Thiol ELISA was then used to determine the A-SH. As shown in Fig. 3C, there was a clear reduction in A-SH from P1 (29.7 ± 6.5%) to P3 (17.2 ± 8%) and P5 (12.08 ± 5.8%) in EVsWTand the reduction was more pronounced in EVSG93A. Using non-reducing SDS-PAGE, we further confirmed the presence of disulfide cross-linked SOD1 of high molecular weight accumulated in both the EVsWTand EVsG93A(Fig. 3D). The data together demonstrate that senescent hSOD1 -carrying NSCs secrete EVs that contain a considerable amount of oxidized SOD1 .

[0075] EXAMPLE 4. Exogenous EVs from senescent NSCs induce aging-like phenotypes

[0076] We further tested the effect of EVs from senescent NSCs on young NSCs. EVsWTand EVSG93Aat P5 were first labeled with Texas Red using Exo-Fect siRNA / miRNA Transfection Kit and then proportionally applied to P3 NSCsWTfor 4 hours. Internalization of both EVs was detected in the cytoplasm of NSCsWT. At 24 hours, the labeled EVsWTwere colocalized with misfolded SOD1 that was immunologically detected with the B8H10 antibody (Fig.4A). Meanwhile, immunocytochemistry revealed cytoplasmic translocation of HMGB1 in 43% of the P3 recipient NSCsWTtreated with P5 EVsWT, whereas in the control group HMGB1 translocation was found in less than 2% of the cells. P5 EVsG93Ainduced an even higher rate (73%) of translocation of HMGB1 in the P3 NSCsWT. Meanwhile, 58% of P3 NSCsWTtreated with P5 EVsWTwere positive for senescence-associated beta-galactosidase (SA-p-Gal) as compared to 13% in the control and 73% in the P5 EVsG93A-treated group (Fig. 4B).

[0077] After confirming the senescence-inducing effect, we further investigated the effects of EVsWTfrom different passages on proliferation of NSCs. We categorized proliferation patterns of NSCs into three groups based on the distance of Ki67-positive cells to the neurosphere cluster. There were no differences among cells in group A (<20 pm from neurosphere) and group C (>200 pm). In group B, where the cells are 20-200 pm from the neurosphere, the number of Ki67+cells was significantly reduced to 60% in P3 EVsWT-treated cells and 26.7% in P5 EVsWT-treated cells as compared to the control group (Fig. 5A). P16, a cyclin-dependent kinase inhibitor that promotes G1 cell cycle arrest, was significantly increased by 1.6-fold in the P5 EVsWT-treated cells compared to the non-treated control, although cells treated with P3 EVsWTdidn’t show a significant difference (Fig. 5B). Upregulation of the aging marker P53 was by 1.7-fold in the P5 EVsWT-treated cells compared to the control (Fig. 5C). We then tested if removal of misfolded SOD1 from the EVsWTby GST-CT4 affinity capture would restore proliferation of NSCs. Intact exosomes were incubated with GST-CT4 bound Glutathione Sepharose, and the GST-CT4 pulled down an SOD1 band from the lysates of P5 EVsWT, compared to GST alone (Fig. 5D). After the affinity capture, the treated P5 EVsWTwas applied to P3 NSCs. The number of Ki67+-positive cells was restored to 28 ± 7.5% from 17. ± 5.5% in GST-alone control (Fig. 5D). EXAMPLE 5. Blocking senescence-inducing SOD1 mitigates neurotoxicity

[0078] We further examined the effect of CT4 on self-seeding aggregation of SOD1. As shown in Fig. 6A, pre-incubation of CT4 for 24 hours with isolated P5 EVsWTresulted in a 53% decrease of SOD1 in the mild detergent-insoluble fraction while SOD1 in the soluble fraction was not significantly affected. Application of P5 EVsWTto the recipient P3 NSCsWTin differentiation medium for 24 hours induced a significant loss of MAP2-positive neurons and an increased release of lactate dehydrogenase (LDH), which was similar to the toxicity induced by P5 EVsG93A. 2 hours pre-incubation of CT4 to P5 EVsWTabolished the neurotoxicity of misfolded SOD1 (Fig. 6).

[0079] EXAMPLE 6. Knockdown of misfolded hSOD1 Enhances hBMSCs Growth and Proliferation

[0080] The hBMSCs were acquired at passage 4 (P4) from Thermo Fisher, and we initiated treatment and observed the effects from passage 7 (P7). At this stage, hBMSCs exhibited a fibroblast-like morphology, characterized by elongated, spindle-shaped forms, abundant cytoplasm, and large nuclei, as shown in Fig. 7A. The manufacturer's guidelines indicate that cells at P7 are considered as low passage with optimal multipotency and growth characteristics. Studies suggest that low oxygen tension increases the proliferation and differentiation potential of hBMSCs in vitro and in vivo

[0059] . Therefore, in our initial study, hBMSCs were allocated into four groups based on experimental conditions: normoxic (21% O2), low oxygen tension (8% O2), or each condition with or without the application of CT4 treatment at a dosage of 5 pM for 72 h. However, the subsequent analysis demonstrated that the reduced oxygen tension condition significantly promoted the growth of hBMSCs (Fig. 7B). Specifically, under 8% O2conditions, the total cell count rose from 1.35 ± 0.25 x 105in 21 % O2to 1.91 ± 0.2 x 105. Further, we explored whether the degrading misfolded hSOD1 could enhance the proliferation of hBMSCs. The CT4-directed misfolded hSOD1 knockdown demonstrated a comparable effect to the response observed under 8% O2conditions on hBMSCs proliferation, achieving a cell count of 1.85 ± 0.2 x 105. Notably, when combined with hypoxic conditions, the effect of CT4 treatment was significantly enhanced, doubling the cell count to 2.29 ± 0.2 x 105per well (Fig. 7B). We assessed the total protein content and calculated the protein content per cell. Statistical analysis revealed a significant difference under normoxic conditions despite the reduction in protein content per cell being small, approximately 10%, in the CT4 treatment group. Under conditions of low oxygen tension, the reduction in protein content per cell was more pronounced, approximately 20%, and further exacerbated to approximately 43% in the group exposed to both low oxygen tension and CT4 treatment, as shown in Fig. 7C. These findings align with morphological observations, where cell sizes in the hypoxia, CT4, and hypoxia plus CT4 groups were smaller compared to the control group (Fig. 7C).

[0081] EXAMPLE 7. Knockdown of Misfolded hSOD1 Promotes hBMSCs Proliferation Without Affecting Their Differentiation

[0082] To accurately compare growth kinetics, growth curves for hBMSCs, both with and without misfolded hSOD1 knockdown under normoxic conditions, were plotted. The manufacturer notes that hBMSCs, when passaged beyond P10, exhibit a marked decrease in multipotency and a reduction in proliferation rates. For this study, hBMSCs were collected and quantified from passages 7 to 10 to construct cell growth curves (Fig. 8A). The analysis revealed an increase in cell proliferation in the misfolded hSOD1 knockdown hBMSCs, demonstrated by a reduction in population doubling time compared to the control. The population doubling time (PDT) was reduced from 97.2 ± 5.1 h to 71.7 ± 8.1 h in passages 7 to 8, from 105.2 ± 9.8 h to 75.8 ± 3.2 h in passages 8 to 9, and from 124.4 ± 12.1 h to 97.4 ± 10.8 h in passages 9 to 10, as shown in Fig. 8B. These results further support the hypothesis that counteracting the effects of misfolded hSOD1 can improve the proliferative capacity of hBMSCs under normoxic conditions.

[0083] To assess the differentiation potential towards osteoblasts and adipocytes, hBMSCs were then cultured in CT4-supplemented adipogenesis and osteogenesis differentiation medium. The differentiation capability of hBMSCs was evaluated by staining with Alizarin Red S and Oil Red O for osteogenesis and adipogenesis, respectively. After 28 days of differentiation, calcium deposits in hBMSCs were assessed using Alizarin Red S staining, which showed no significant differences in staining intensity between the normal and knockdown groups, as presented in Figs. 9A and B. Additionally, following 14 days of differentiation, analysis of Oil Red O staining revealed that both the normal and misfolded hSOD1 knockdown hBMSCs displayed similar levels of lipid droplets, as illustrated in Figs. 9C and D. These findings indicate that CT4-directed knockdown of misfolded hSOD1 does not impact the adipogenic and osteogenic differentiation capacities of hBMSCs compared to untreated cells.

[0084] EXAMPLE 8. Extended culture of hBMSCs led to hSOD1 misfolding, concurrent with hSOD1 oxidation.

[0085] Our recent study demonstrated that the oxidation of SOD1 significantly accelerates cellular senescence in neural stem cells

[0063] . This led us to hypothesize that the knockdown of misfolded SOD1 might be an effective strategy to mitigate SOD1 oxidation, thereby potentially enhancing mesenchymal stem cells' sternness and therapeutic efficacy. To assess the impact of reducing misfolded human superoxide dismutase 1 (hSOD1 ) on its oxidation during both normal (P7) and extended (P15) cultures of hBMSCs, we engineered a pGEX- CT4 vector to examine the direct interaction between CT4 and misfolded SOD1 through the use of bacterially expressed GST-fusion proteins. Whole-cell lysates were incubated with the CT4-GST recombinant fusion protein as bait. Our findings revealed that both the P7 and P15 hBMSCs cultures exhibited significant levels of misfolded hSOD1 , as demonstrated by their affinity binding in the CT4-GST pull-down assay, as shown in Fig. 10A. Comparative analysis indicated that the P15 lysate contained higher levels of misfolded hSOD1 relative to the P7 lysate (Fig. 10B), suggesting that hSOD1 from hBMSCs is increasingly prone to misfolding with extended culture duration. Subsequently, we analyzed the oxidative status of hSOD1 in these two cell batches. Fig. 10C illustrates that, in parallel with misfolding, both P7 and P15 hBMSCs exhibited oxidized hSOD1 , as evidenced by a 17 kDa monomer band in the MalPEG conjugation analysis. Treatment with MalPEG was anticipated to modify non-oxidized hSOD1 , resulting in the appearance of higher molecular weight MP1 and MP2 bands. By facilitating the degradation of misfolded hSOD1 through CT4, we observed a notable decrease in hSOD1 oxidation, as evidenced by the comparison between CT4-treated and untreated samples (Fig. 10D and E).

[0086] EXAMPLE 9. Prion-like transmission of misfolded hSOD1 via EVs inhibits hBMSCs proliferation

[0087] Building on our earlier work, we have documented that extracellular vesicles (EVs) from aged neural stem cells (NSCs) contain misfolded and oxidized hSOD1

[0063] . Consequently, to evaluate whether the EVs originating from hBMSCs could be involved in misfolded spreading, we assessed the presence of misfolded hSOD1 in the EVs lysate. A gradual increase in misfolded hSOD1 levels was noted in EV lysates, rising from 7 ± 3% at P7 to 36 ± 7% of total hSOD1 at P15, as demonstrated by misfolded hSOD1 ELISA (Fig. 11 A). This represents approximately a 5.14-fold increase in the level of misfolded hSOD1 from P7 to P15. Subsequently, P7 hBMSCs underwent treatment with CT4, following their pretreatment with EVs isolated from P15 hBMSCs. CT4 treatment resulted in a significant reduction of hSOD1 oxidation, specifically, a decrease from 4.3 ± 0.6% to 1.1 ± 0.3%, as shown in Fig. 11 B and C. Our data also showed that CT4 treatment alleviates the effect of P15 EVs, significantly restored the proliferation of hBMSCs, as shown in Fig. 11 D and E. Notably, this increase in cell count became more pronounced with observation up to 72 hours.

[0088] EXAMPLE 10. Methods

[0089] Animals, primary neural stem cell culture and differentiation

[0090] Transgenic mice carrying human G93A mutant SOD1 (B6.Cg-Tg(SOD1*G93A)1Gur / J; 004435) and wild-type human SOD1 (B6.Cg-Tg(SOD1)2Gur / J; 002298) were obtained from the Jackson Laboratory. Mice carrying the human SOD1 transgene were identified by PCR screening of ear punch DNA using a mouse SOD1 forward primer (5'- CATCAGCCCTAATCCATCTGA-3', SEQ ID NO:3) and a reverse primer (5 - CGCGACTAACAATCAAAGTGA-3', SEQ ID NO:4). The strains were maintained by breeding hemizygous carrier males to female mice with a C57BL / 6 background. Colonies are maintained in the Central Animal Care Services, University of Manitoba, and the use of the mice was performed in accordance with the Guide of Care and Use of Experimental Animals of the Canadian Council on Animal Care.

[0091] As previously described

[0024] , time pregnant female C57BL / 6 mice mated with transgenic male mice carrying the full-length wild-type human SOD1 (hSOD1WT) or the G93A mutation of human SOD1 (hSOD1G93A) gene were humanely euthanized by CO2 gas followed by cervical dislocation, and embryos were removed. All animal experiments were performed in accordance with the Guide of Care and Use of Experimental Animals of the Canadian Council on Animal Care. The day of the positive vaginal plug was considered as E0.5 of pregnancy and embryos were collected at E14.5 and placed in Earle’s Balanced Salt Solution (EBSS) solution on ice. Transgenic embryos expressing the full length human SOD1 gene were genotyped by PCR of DNA obtained from mouse tails. The brain was removed, and cortices were dissected out, triturated and then passed through a 40 pM strainer. Cells were maintained in Complete StemPro NSC media containing basic fibroblast growth factor (bFGF) (20 ng / ml) and human epidermal growth factor (hEGF) (20 ng / ml) to form neurospheres in 5-7 days. When the neurospheres were 150-200 pm in diameter, they were disassociated for subculture. For NSC differentiation, the NSCs were harvested by centrifugation and plated on a poly-L-ornithine and laminin coated 6-well plates in complete StemPro NSC medium. Enriched neuronal culture was obtained by switching culture medium to neurobasal / B27 and confirmed by MAP-2 staining.

[0092] Selective knockdown of misfolded SOD1 from NSCs

[0093] We reported a CT4-directed degradation of misfolded SOD1 through chaperone- mediated autophagy (Fig. 1A). Briefly, the CT4 fusion peptide consists of the transduction domain of HIV TAT protein capable of crossing the cell membrane

[0025] , the CT4 sequence that selectively binds to misfolded SOD1 , and the CMA targeting motif (CTM) that is destined for lysosomes

[0026] . The peptide binds specifically to the derlin-1 binding region of SOD1 , which is exposed only when SOD1 is misfolded, and robustly removes misfolded SOD1 through lysosomal degradation. Knockdown of misfolded SOD1 in NSCs was achieved by application of the CT4 fusion peptide to the culture medium at 5 pM once every other day.

[0094] CT4-GST pull-down assay

[0095] Direct binding between CT4 and misfolded SOD1 was assessed using bacterially expressed CT4-Glutathione S-transferase (GST)-fused proteins. Briefly, the derlin1 -CT4 epitope (FLYRWLPSRRGG, SEQ ID NO:5) cloned into the pGEX4T-1 vector was transformed into BL21 competent cells. A single clone was cultured in LB media containing 50 pg / ml ampicillin. Expression of GST or GST-fused GGGGS-CT4 was induced at an OD600 of approximately 0.6 with 0.5 mM IPTG. The bacteria pellet was re-suspended in lysis buffer (30 mM Tris-CI (pH 7.5), 0.1 mM NaCI, 1 mM DTT, 1% NP-40, and protease inhibitors), sonicated and centrifuged at 12,000 rpm for 30 min. Soluble fraction containing GST or GST-GGGGS- CT4 fusion proteins was incubated with glutathione-Sepharose 4B beads (GE Healthcare Life Sciences) for 1 hour to immobilize GST or GST-GGGGS-CT4. To identify direct binding between misfolded SOD1 and CT4, the immobilized GST-fused proteins were incubated with samples at 4°C for 2 hours. After extensive washing thrice with PBS, the bound proteins were separated by SDS-PAGE and detected by immunoblotting.

[0096] Immunocytochemistry

[0097] Cells on coverslips were fixed in 4% paraformaldehyde in PBS pH 7.4 for 15 minutes at room temperature and then washed three times with PBS. Samples were incubated for 10 minutes in PBS containing 0.25% Triton X-100 (PBST) to improve the penetration of antibodies. After washing with PBS, the coverslips were incubated in 1% BSA in PBST for 30 minutes to block nonspecific binding of the antibodies. After blocking, samples were incubated with primary antibodies in 1% BSA overnight at 4°C. Following three additional washes, appropriate secondary antibodies were applied and incubated for 1 hour at room temperature in the dark. After being washed three final times, cells were incubated with Hoechst 33342 (Calbiochem) to counterstain for nuclei, and then coverslips were mounted with a drop of mounting medium (Dako North America, Inc. Carpinteria, CA 93013, USA). Fluorescence pictures were taken on a Carl Zeiss Axiolmager Z2 microscope and processed with Zen Pro imaging software (Zeiss, Germany).

[0098] SOD1 aggregation and thiol oxidation assay.

[0099] Differential extractions were used to assess SOD1 aggregation as previously described [27, 28]. Cells were scraped from the culture dish in PBS and centrifuged to pellet the cells before the pellets were re-suspended in 100 pl 1 x TEN (10 mM Tris, 1 mM EDTA, and 100 mM NaCI). The re-suspended cell culture pellets were then mixed with an equal volume of extraction buffer A (1 x TEN, 1 % Nonidet P40, and protease inhibitor cocktail 1 OO dilution) and sonicated with a probe sonicator at 50% output for 30 s (50 W at 20kHz, FB50, Fisher Scientific, Pittsburgh, PA, USA). The resulting lysate was centrifuged for 5 min at > 100,000 x g in an ultracentrifuge (Optimal L-90k, Beckman Coulter, USA) to separate pellet (P1 ) from the supernatant (S1 ). The supernatant (S1 ) was decanted and saved for analysis. The pellet (P1 ) was washed with 200 pl of extraction buffer B (1 x TEN and 0.5% Nonidet P40) by sonication (50% for 30 s). The extract was then centrifuged for 5 min at >100,000 x g in a Beckman Airfuge to separate a pellet (P2) from the supernatant. The P2 fraction was resuspended in buffer C (1 x TEN, 0.5% Nonidet P40, 0.25% SDS, and 0.5% deoxycholic acid) by sonication (50% power setting for 30 s) and saved for analysis. Protein concentration was measured in S1 and P2 fractions by the BCA methods as described by the manufacturer (Pierce). For sandwich ELISA, a Human Cu / ZnSOD Matched Antibody Pair Kit (Thermo Fisher, #BMS222MST) was used to detect and quantify protein levels of human Cu / ZnSOD in cell lysates following the manufacturer’s protocol. To assess the thiol-disulfide status of the SOD1 , aliquots were incubated in an aerobic chamber at room temperature overnight to allow oxidation of cysteine while anaerobic preserved samples were used as a reference. Capture antibodies (SOD1 FL-154, 0.2 pg / mL) were adsorbed on wells of an ELISA plate (F96 cert. MaxiSorp™ Immuno-plate: Nunc, Roskilde, Denmark), to which samples containing the same amount of hSOD1 were applied. Maleimide-activated HRP was then used to determine the thiol content of the captured SOD1 among groups as the activated HRP presents an available maleimide group that reacts with sulfhydryl-containing SOD1. Absorbance was measured on a Synergy Mx multi-mode microplate reader (BioTek).

[0100] MalPEG (methoxy polyethylene glycol-maleimide 5000, Sigma) modification was employed to detect the oxidation of sulfhydryl groups in specific proteins. MalPEG forms a covalent bond with a protein with free sulfhydryl groups, and the MalPEG-protein conjugate can be identified as a shift in the western blot pattern. As previously described, cell lysates were modified with MalPEG at a final concentration of 3 mM for 1 h at 25 °C. The reaction was quenched by 5% p-mercaptoethanol and then subjected to 12% SDS-PAGE. To assess total hSOD1 levels, densitometry was performed on three distinct bands: a non-conjugated band and two bands corresponding to MalPEG conjugated forms, MP1 and MP2. Here, the non-conjugated band is indicative of oxidized hSOD1. The proportion of oxidized hSOD1 will be calculated by comparing the intensity of the non-conjugated band to the combined intensities of all three bands, thereby reflecting the oxidized fraction. Additionally, to ensure the accuracy and reliability of our measurements within the detection range, samples not treated with MalPEG will be included in each experimental set.

[0101] Electron microscopy (EM).

[0102] EVs prepared from culture media were fixed in 2% paraformaldehyde, 3% glutaraldehyde and 0.1 M Sorensen's buffer (pH=7.4) for 2 h at room temperature. The fixed EVs were ultracentrifuge and washed with 0.1 M Sorensen’s buffer containing 5% sucrose. Fixed vesicles were absorbed onto 200-mesh copper grids (Electron Microscopy Sciences, Hatfield, PA), and stained with 0.5% aqueous uranyl acetate for 30 s and viewed on a transmission electron microscope (Philips CM-10, Hillsboro, OR, USA).

[0103] Cell Culture and Calculation of Population Doubling Time

[0104] Human mesenchymal stem cells derived from bone marrow hBMSCs were acquired from Thermo Fisher Scientific (Catalog #A15652, Waltham, MA, USA) and maintained in DMEM / F-12 medium supplemented with 5% exosome-depleted FBS (A2720801 , Thermo Fisher Scientific Waltham, MA, USA). Approximately 3x105cells were seeded into 75 cm2culture flasks. These cultures were then incubated at 37°C in an atmosphere containing 5% CO2. For low oxygen tension culture, hBMSCs were incubated in a tri-gas incubator with a setting of 8% O2 and 5% CO2. Cell culture was conducted through passages 5 to 15. The medium was changed every 3 days until the monolayer of adherent cells reached 70-80% confluence. Cell passaging was performed using trypsin-EDTA solution (0.25%, Sigma Aldrich, USA). The number of cells and viability by trypan Blue exclusion test was evaluated using an Automated Cell Counter (TC20, Bio-Rad, Hercules, CA.). To assess growth characteristics, hBMSCs were seeded in 6-well plates at a density of approximately 1 x105cells per well in triplicate. Cells were trypsinized and counted to produce cell growth curves. To compare the in-vitro proliferation rate, the population doubling time (PDT) value was calculated using the formula PDT = T x In2 / In (Xe / Xb), in which T is the incubation time in hours, Xb represents the cell number at the beginning of the incubation time, and Xe corresponds to the cell number at the end of incubation time. hBMSCs Differentiation Capability hBMSCs were counted and plated at a density of 1 x 105cells per well in a 6-well plate. Upon reaching approximately 80% confluency, cells were treated with an osteogenesis differentiation medium (Life Technologies, A10072-01 ) or adipogenesis differentiation medium (Life Technologies, A10070-01). The medium was changed twice a week for 2 to 4 weeks. To evaluate the differentiation potential towards osteogenesis and adipogenesis, cells were fixed in 10% neutral buffered formalin. Following this, cells were stained according to the manufacturer's instructions using Alizarin-Red Staining Solution (Sigma, TMS-008-C) for osteogenesis and Oil Red O solution (Sigma, 01391 -250ML) for adipogenesis, respectively. Cells were stained with 40 mM Alizarin red S solution for Alizarin staining. The plates were incubated at room temperature for 20 min, then washed and air-dried. Bound calcium was released by adding 1 mL of acetic acid, and the mixture was incubated for 20 min. The solution was collected for OD 405 measurement. For Oil Red O staining, cells were stained with 0.3% Oil Red O staining solution for 20 min and then washed with water. 100% isopropanol was added to each well and incubated for 20 min at room temperature. Eluates from each well were transferred to a 96-well plate for optical density readings at 500 nm.

[0105] Conditioned media and extracellular vesicles (EVs) isolation

[0106] The conditioned medium from the hBMSCs was harvested every other day and subjected to centrifugation at 2,000 g for 10 minutes at 4°C, followed by further centrifugation at 10,000 g for 30 minutes at 4°C to remove cells, cellular membranes, and debris. Subsequently, the supernatant was filtered through 0.22 pm pore-size filters. ExoQuick-TC® ULTRA kit for Tissue Culture Media (Catalog #EQULTRA-20TC-1 ; System Biosciences, Palo Alto, CA) was used to isolate EVs, following the manufacturer's recommended protocol. P15 hBMSCs-derived EVs were applied to P7 hBMSCs for the transfer study. The amount of EVs collected from P15 cells was adjusted to match the number of recipients of P7 hBMSCs.

[0107] Western Blot

[0108] Following protein concentration determination using the Pierce™ BCA Protein Assay Kit (ThermoFisher, Waltham, MA), samples were heated for 5 minutes with Laemmli sample buffer containing 2.5% p-mercaptoethanol. They were then loaded onto 12% TGX Stain-Free polyacrylamide gels (Bio-Rad, Hercules, CA, Cat #1610185) for SDS-PAGE and subsequently transferred onto PVDF membranes using the Trans-Blot Turbo Transfer System (Bio-Rad, Hercules, CA, USA). The membranes were then blocked using 5% fat-free dry milk in Tris-buffered saline (10 mM Tris-HCI, pH 7.5, 150 mM NaCI) with 0.05% Tween-20 for an hour, followed by overnight incubation at 4°C with the primary antibody, anti-hSOD1 (ab52950, RRID: AB 2193891 , 1 :2000, Abeam, Cambridge, UK). After washing three times with TBST buffer, the membranes were incubated with the secondary antibodies for an hour at room temperature. Protein bands were then detected using the enhanced chemiluminescence reagent (ECL Prime, RPN2232, GE Healthcare, Chicago, IL, USA) and imaged on the ChemiDoc MP imaging system (Bio-Rad, Hercules, CA, USA).

[0109] Statistical analysis.

[0110] All manual counts were performed in a blinded manner except non-objective computational measurements. Data are presented as the mean ± SD. Sample sizes are mentioned for each experiment in the method and results. For statistical comparison between two groups, Student’s t-test was used. Multiple comparisons were performed by One-way ANOVA followed by Bonferroni’s Multiple Comparison test, two-way ANOVA followed by Sidak's multiple comparisons test. Differences were considered to be statistically significant when P<0.05. The scope of the claims should not be limited by the preferred embodiments set forth in the examples but should be given the broadest interpretation consistent with the description as a whole.

[0111] REFERENCES

[0112] 1. Christian KM, Song H, Ming GL. Functions and dysfunctions of adult hippocampal neurogenesis. Annu Rev Neurosci. 2014;37:243-62. Epub 2014 / 06 / 07. doi: 10.1146 / annurev- neuro-071013-014134. PubMed PMID: 24905596; PubMed Central PMCID: PMCPMC5531058.

[0113] 2. Goncalves JT, Schafer ST, Gage FH. Adult Neurogenesis in the Hippocampus: From Stem Cells to Behavior. Cell. 2016;167(4):897-914. Epub 2016 / 11 / 05. doi: 10.1016 / j. cell.2016.10.021 . PubMed PMID: 27814520.

[0114] 3. Rusanescu G, Mao J. Immature spinal cord neurons are dynamic regulators of adult nociceptive sensitivity. J Cell Mol Med. 2015;19(10):2352-64. Epub 2015 / 08 / 01. doi: 10.1111 / jcmm.12648. PubMed PMID: 26223362; PubMed Central PMCID: PMCPMC4594677.

[0115] 4. Meletis K, Barnabe-Heider F, Carlen M, Evergren E, Tomilin N, Shupliakov O, et al. Spinal cord injury reveals multilineage differentiation of ependymal cells. PLoS Biol. 2008;6(7):e182. Epub 2008 / 07 / 25. doi: 10.1371 / journal.pbio.0060182. PubMed PMID: 18651793; PubMed Central PMCID: PMCPMC2475541 .

[0116] 5. Barnabe-Heider F, Goritz C, Sabelstrom H, Takebayashi H, Pfrieger FW, Meletis K, et al. Origin of new glial cells in intact and injured adult spinal cord. Cell Stem Cell. 2010;7(4):470-82. Epub 2010 / 10 / 05. doi: 10.1016 / j.stem.2010.07.014. PubMed PMID: 20887953.

[0117] 6. Leeman DS, Hebestreit K, Ruetz T, Webb AE, McKay A, Pollina EA, et al. Lysosome activation clears aggregates and enhances quiescent neural stem cell activation during aging. Science. 2018;359(6381):1277-83. Epub 2018 / 03 / 29. doi: 10.1126 / science.aag3048. PubMed PMID: 29590078; PubMed Central PMCID: PMCPMC5915358.

[0118] 7. Llamas E, Alirzayeva H, Loureiro R, Vilchez D. The intrinsic proteostasis network of stem cells. Curr Opin Cell Biol. 2020;67:46-55. Epub 2020 / 09 / 06. doi: 10.1016 / j.ceb.2020.08.005. PubMed PMID: 32890906.

[0119] 8. Enwere E, Shingo T, Gregg C, Fujikawa H, Ohta S, Weiss S. Aging results in reduced epidermal growth factor receptor signaling, diminished olfactory neurogenesis, and deficits in fine olfactory discrimination. J Neurosci. 2004;24(38):8354-65. Epub 2004 / 09 / 24. doi: 10.1523 / JNEUROSCI.2751 -04.2004. PubMed PMID: 15385618; PubMed Central PMCID: PMCPMC6729689.

[0120] 9. Capilla-Gonzalez V, Cebrian-Silla A, Guerrero-Cazares H, Garcia-Verdugo JM, Quinones-Hinojosa A. Age-related changes in astrocytic and ependymal cells of the subventricular zone. Glia. 2014;62(5):790-803. Epub 2014 / 03 / 29. doi: 10.1002 / glia.22642. PubMed PMID: 24677590; PubMed Central PMCID: PMCPMC4322944.

[0121] 10. Giachino C, Basak O, Lugert S, Knuckles P, Obernier K, Fiorelli R, et al. Molecular diversity subdivides the adult forebrain neural stem cell population. Stem Cells. 2014;32(1):70-84. Epub 2013 / 08 / 22. doi: 10.1002 / stem.1520. PubMed PMID: 23964022; PubMed Central PMCID: PMCPMC4259462.

[0122] 11. Kuhn HG, Dickinson-Anson H, Gage FH. Neurogenesis in the dentate gyrus of the adult rat: age-related decrease of neuronal progenitor proliferation. J Neurosci. 1996;16(6):2027-33. Epub 1996 / 03 / 15. doi: 10.1523 / JNEUROSCI.16-06-02027.1996. PubMed PMID: 8604047; PubMed Central PMCID: PMCPMC6578509.

[0123] 12. Kobayashi T, Piao W, Takamura T, Kori H, Miyachi H, Kitano S, et al. Enhanced lysosomal degradation maintains the quiescent state of neural stem cells. Nat Commun. 2019;10(1 ):5446. Epub 2019 / 12 / 01. doi: 10.1038 / s41467-019-13203-4. PubMed PMID: 31784517; PubMed Central PMCID: PMCPMC6884460.

[0124] 13. Blander G, de Oliveira RM, Conboy CM, Haigis M, Guarente L. Superoxide dismutase 1 knock-down induces senescence in human fibroblasts. J Biol Chem. 2003;278(40):38966-9. Epub 2003 / 07 / 23. doi: 10.1074 / jbc.M307146200. PubMed PMID: 12871978.

[0125] 14. Noblanc A, Klaassen A, Robaire B. The Exacerbation of Aging and Oxidative Stress in the Epididymis of Sod1 Null Mice. Antioxidants (Basel). 2020;9(2). Epub 2020 / 02 / 15. doi: 10.3390 / antiox9020151 . PubMed PMID: 32054065; PubMed Central PMCID: PMCPMC7071042.

[0126] 15. Xu WC, Liang JZ, Li C, He ZX, Yuan HY, Huang BY, et al. Pathological hydrogen peroxide triggers the fibrillization of wild-type SOD1 via sulfenic acid modification of Cys-111 . Cell death & disease. 2018;9(2):67. Epub 2018 / 01 / 24. doi: 10.1038 / s41419-017-0106-4. PubMed PMID: 29358575; PubMed Central PMCID: PMCPMC5833406.

[0127] 16. Chen X, Zhang X, Li C, Guan T, Shang H, Cui L, et al. S-nitrosylated protein disulfide isomerase contributes to mutant SOD1 aggregates in amyotrophic lateral sclerosis. J Neurochem. 2013;124(1):45-58. doi: 10.1111 / jnc.12O46. PubMed PMID: 23043510.

[0128] 17. Chen X, Shang H, Qiu X, Fujiwara N, Cui L, Li XM, et al. Oxidative modification of cysteine 111 promotes disulfide bond-independent aggregation of SOD1. Neurochem Res. 2012;37(4):835-45. doi: 10.1007 / s11064-011 -0679-8. PubMed PMID: 22219129.

[0129] 18. Chen X, Guan T, Li C, Shang H, Cui L, Li XM, et al. SOD1 aggregation in astrocytes following ischemia / reperfusion injury: a role of NO-mediated S-nitrosylation of protein disulfide isomerase (PDI). J Neuroinflammation. 2012;9:237. doi: 10.1186 / 1742-2094-9-237. PubMed PMID: 23061969; PubMed Central PMCID: PMC3526400.

[0130] 19. Chattopadhyay M, Valentine JS. Aggregation of copper-zinc superoxide dismutase in familial and sporadic ALS. Antioxid Redox Signal. 2009;11 (7):1603-14. doi: 10.1089 / ARS.2009.2536. PubMed PMID: 19271992; PubMed Central PMCID: PMC2842589.

[0131] 20. Kong J, Xu Z. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J Neurosci. 1998;18(9):3241 -50. PubMed PMID: 98213703.

[0132] 21. Higgins C, Jung C, Xu Z. ALS-associated mutant SOD1G93A causes mitochondrial vacuolation by expansion of the intermembrane space and involvement of peroxisomes. BMC Neurosci. 2003;4:1-14.

[0133] 22. Guareschi S, Cova E, Cereda C, Ceroni M, Donetti E, Bosco DA, et al. An overoxidized form of superoxide dismutase found in sporadic amyotrophic lateral sclerosis with bulbar onset shares a toxic mechanism with mutant SOD1. Proc Natl Acad Sci U S A. 2012;109(13):5074-9. doi: 10.1073 / pnas.1115402109. PubMed PMID: 22416121 ; PubMed Central PMCID: PMC3324021.

[0134] 23. Shafiq K, Sanghai N, Guo Y, Kong J. Implication of post-translationally modified SOD1 in pathological aging. Geroscience. 2021 ;43:507-15. Epub 2021 / 02 / 21. doi: 10.1007 / s11357- 021 -00332-2. PubMed PMID: 33608813. 24. Li W, Guan T, Zhang X, Wang Z, Wang M, Zhong W, et al. The Effect of Layer-by- Layer Assembly Coating on the Proliferation and Differentiation of Neural Stem Cells. ACS applied materials & interfaces. 2015;7(5):3018-29. Epub 2014 / 10 / 28. doi: 10.1021 / am504456t. PubMed PMID: 25347385.

[0135] 25. Schwarze SR HA, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science. 1999;285(5433): 1569-72.

[0136] 26. Fan X, Jin WY, Lu J, Wang J, Wang YT. Rapid and reversible knockdown of endogenous proteins by peptide-directed lysosomal degradation. Nat Neurosci. 2014;17(3):471-80. doi: 10.1038 / nn.3637. PubMed PMID: 24464042; PubMed Central PMCID: PMC3937121.

[0137] 27. Karch CM, Borchelt DR. A limited role for disulfide cross-linking in the aggregation of mutant SOD1 linked to familial amyotrophic lateral sclerosis. J Biol Chem. 2008;283(20):13528-37. Epub 2008 / 03 / 05. doi: 10.1074 / jbc.M800564200. PubMed PMID: 18316367; PubMed Central PMCID: PMCPMC2376231 .

[0138] 28. Wang J, Slunt H, Gonzales V, Fromholt D, Coonfield M, Copeland NG, et al. Copper- binding-site-null SOD1 causes ALS in transgenic mice: aggregates of non-native SOD1 delineate a common feature. Hum Mol Genet. 2003;12(21):2753-64. Epub 2003 / 09 / 11. doi: 10.1093 / hmg / ddg312. PubMed PMID: 12966034.

[0139] 29. Grad LI, Yerbury JJ, Turner BJ, Guest WC, Pokrishevsky E, O'Neill MA, et al. Intercellular propagated misfolding of wild-type Cu / Zn superoxide dismutase occurs via exosome-dependent and -independent mechanisms. Proc Natl Acad Sci U S A. 2014;111 (9):3620-5. doi: 10.1073 / pnas.1312245111 . PubMed PMID: 24550511 ; PubMed Central PMCID: PMC3948312.

[0140] 30. Nicaise AM, Wagstaff LJ, Willis CM, Paisie C, Chandok H, Robson P, et al. Cellular senescence in progenitor cells contributes to diminished remyelination potential in progressive multiple sclerosis. Proc Natl Acad Sci U S A. 2019;116(18):9030-9. Epub 2019 / 03 / 27. doi: 10.1073 / pnas.1818348116. PubMed PMID: 30910981 ; PubMed Central PMCID: PMCPMC6500153.

[0141] 31. Kregel KC, Zhang HJ. An integrated view of oxidative stress in aging: basic mechanisms, functional effects, and pathological considerations. Am J Physiol Regul Integr Comp Physiol. 2007;292(1):R18-36. Epub 2006 / 08 / 19. doi: 10.1152 / ajpregu.00327.2006. PubMed PMID: 16917020.

[0142] 32. Petrucelli L, Dawson TM. Mechanism of neurodegenerative disease: role of the ubiquitin proteasome system. Ann Med. 2004;36(4):315-20. Epub 2004 / 07 / 01. doi: 10.1080 / 07853890410031948. PubMed PMID: 15224658.

[0143] 33. Vonk WIM, Rainbolt TK, Dolan PT, Webb AE, Brunet A, Frydman J. Differentiation Drives Widespread Rewiring of the Neural Stem Cell Chaperone Network. Mol Cell. 2020;78(2):329-45 e9. Epub 2020 / 04 / 09. doi: 10.1016 / j.molcel.2020.03.009. PubMed PMID: 32268122; PubMed Central PMCID: PMCPMC7288733.

[0144] 34. Lee JC, Jin Y, Jin J, Kang BG, Nam DH, Joo KM, et al. Functional neural stem cell isolation from brains of adult mutant SOD1 (SOD1 (G93A)) transgenic amyotrophic lateral sclerosis (ALS) mice. Neurol Res. 2011 ;33(1):33-7. Epub 2010 / 09 / 03. doi: 10.1179 / 016164110X12807570509899. PubMed PMID: 20810028. 35. Silverman JM, Christy D, Shyu CC, Moon KM, Fernando S, Gidden Z, et al. CNS- derived extracellular vesicles from superoxide dismutase 1 (SOD1 )(G93A) ALS mice originate from astrocytes and neurons and carry misfolded SOD1. J Biol Chem. 2019;294(10):3744-59. Epub 2019 / 01 / 13. doi: 10.1074 / jbc.RA118.004825. PubMed PMID: 30635404; PubMed Central PMCID: PMCPMC6416428.

[0145] 36. Tokuda E, Takei Yl, Ohara S, Fujiwara N, Hozumi I, Furukawa Y. Wild-type Cu / Zn- superoxide dismutase is misfolded in cerebrospinal fluid of sporadic amyotrophic lateral sclerosis. Mol Neurodegener. 2019;14(1 ):42. Epub 2019 / 11 / 21. doi: 10.1186 / s13024-019- 0341-5. PubMed PMID: 31744522; PubMed Central PMCID: PMCPMC6862823.

[0146] 37. Niwa J, Yamada S, Ishigaki S, Sone J, Takahashi M, Katsuno M, et al. Disulfide bond mediates aggregation, toxicity, and ubiquitylation of familial amyotrophic lateral sclerosis- linked mutant SOD1. J Biol Chem. 2007;282(38):28087-95. doi: 10.1074 / jbc.M704465200. PubMed PMID: 17666395.

[0147] 38. Forman HJ, Fukuto JM, Torres M. Redox signaling: thiol chemistry defines which reactive oxygen and nitrogen species can act as second messengers. Am J Physiol Cell Physiol. 2004;287(2):C246-56. PubMed PMID: 15238356.

[0148] 39. Woo HA, Chae HZ, Hwang SC, Yang KS, Kang SW, Kim K, et al. Reversing the inactivation of peroxiredoxins caused by cysteine sulfinic acid formation. Science. 2003;300(5619):653-6. PubMed PMID: 12714748.

[0149] 40. Claiborne A, Yeh JI, Mallett TC, Luba J, Crane EJ, 3rd, Charrier V, et al. Protein- sulfenic acids: diverse roles for an unlikely player in enzyme catalysis and redox regulation. Biochemistry. 1999;38(47) : 15407-16. PubMed PMID: 10569923.

[0150] 41. Une M, Yamakawa M, Watanabe Y, Uchino K, Honda N, Adachi M, et al. SOD1 - interacting proteins: Roles of aggregation cores and protein degradation systems. Neurosci Res. 2021 ;170:295-305. Epub 2020 / 07 / 30. doi: 10.1016 / j.neures.2020.07.010. PubMed PMID: 32726594.

[0151] 42. Guo JL, Lee VM. Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat Med. 2014;20(2):130-8. Epub 2014 / 02 / 08. doi: 10.1038 / nm.3457. PubMed PMID: 24504409; PubMed Central PMCID: PMCPMC4011661 .

[0152] 43. Fujiwara N, Nakano M, Kato S, Yoshihara D, Ookawara T, Eguchi H, et al. Oxidative modification to cysteine sulfonic acid of Cys111 in human copper-zinc superoxide dismutase. J Biol Chem. 2007;282(49):35933-44. PubMed PMID: 17913710.

[0153] 44. Rivera FJ, Silva ME, Aigner L. Editorial: The Vascular Niche in Tissue Repair: A Therapeutic Target for Regeneration. Front Cell Dev Biol. 2017;5:88. Epub 2017 / 10 / 17. doi: 10.3389 / fcell.2017.00088. PubMed PMID: 29034231 ; PubMed Central PMCID: PMCPMC5626825.

[0154] 45. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194-217. Epub 2013 / 06 / 12. doi: 10.1016 / j.cell.2O13.05.039. PubMed PMID: 23746838; PubMed Central PMCID: PMCPMC3836174.

[0155] 46. Cossetti C, Iraci N, Mercer TR, Leonardi T, Alpi E, Drago D, et al. Extracellular vesicles from neural stem cells transfer IFN-gamma via Ifngrl to activate Stall signaling in target cells. Mol Cell. 2014;56(2):193-204. Epub 2014 / 09 / 23. doi: 10.1016 / j.molcel.2014.08.020. PubMed PMID: 25242146; PubMed Central PMCID: PMCPMC4578249.

[0156] 47. Pittenger, M.F., et al., Multilineage potential of adult human mesenchymal stem cells. Science, 1999. 284(5411): p. 143-7.

[0157] 48. Sheng, G., The developmental basis of mesenchymal stem / stromal cells (MSCs). BMC Dev Biol, 2015. 15: p. 44.

[0158] 49. Dominici, M., et al., Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 2006. 8(4): p. 315-7.

[0159] 50. Rungsiwiwut, R., P. Virutamasen, and K. Pruksananonda, Mesenchymal stem cells for restoring endometrial function: An infertility perspective. Reprod Med Biol, 2021. 20(1): p. 13- 19.

[0160] 51. Wada, N., S. Gronthos, and P.M. Bartold, Immunomodulatory effects of stem cells. Periodontol 2000, 2013. 63(1 ): p. 198-216.

[0161] 52. Arthur, A. and S. Gronthos, Clinical Application of Bone Marrow Mesenchymal Stem / Stromal Cells to Repair Skeletal Tissue. Int J Mol Sci, 2020. 21 (24).

[0162] 53. Pittenger, M.F., et al., Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regen Med, 2019. 4: p. 22.

[0163] 54. Nemeth, K. and E. Mezey, Bone marrow stromal cells as immunomodulators. A primer for dermatologists. J Dermatol Sci, 2015. 77(1): p. 11-20.

[0164] 55. Banfi, A., et al., Proliferation kinetics and differentiation potential of ex vivo expanded human bone marrow stromal cells: Implications for their use in cell therapy. Exp Hematol, 2000. 28(6): p. 707-15.

[0165] 56. Gao, Y., et al., Multi-omics analysis of human mesenchymal stem cells shows cell aging that alters immunomodulatory activity through the downregulation of PD-L1. Nat Commun, 2023. 14(1): p. 4373.

[0166] 57. Gala, D.N. and Z. Fabian, To Breathe or Not to Breathe: The Role of Oxygen in Bone Marrow- Derived Mesenchymal Stromal Cell Senescence. Stem Cells Int, 2021. 2021 : p. 8899756.

[0167] 58. Holzwarth, C., et al., Low physiologic oxygen tensions reduce proliferation and differentiation of human multipotent mesenchymal stromal cells. BMC Cell Biol, 2010. 11 : p. 11.

[0168] 59. Mas-Bargues, C., et al., Relevance of Oxygen Concentration in Stem Cell Culture for Regenerative Medicine. Int J Mol Sci, 2019. 20(5).

[0169] 60. Kim, D.S., et al., Effect of low oxygen tension on the biological characteristics of human bone marrow mesenchymal stem cells. Cell Stress Chaperones, 2016. 21 (6): p. 1089- 1099.

[0170] 61. Wang, Y., et al., Superoxide dismutases: Dual roles in controlling ROS damage and regulating ROS signaling. J Cell Biol, 2018. 217(6): p. 1915-1928.

[0171] 62. Gu, S., et al., A liquid-to-solid phase transition of Cu / Zn superoxide dismutase 1 initiated by oxidation and disease mutation. J Biol Chem, 2023. 299(2): p. 102857.

[0172] 63. Guan, T., et al., Oxidized SOD1 accelerates cellular senescence in neural stem cells. Stem Cell Res Ther, 2024. 15(1).

[0173] 64. Guan, T., et al., Selective removal of misfolded SOD1 delays disease onset in a mouse model of amyotrophic lateral sclerosis. Cell Mol Life Sci, 2023. 80(10): p. 304.

[0174] 65. Guo, Y., et al., ALS-linked SOD1 mutations impair mitochondrial-derived vesicle formation and accelerate aging. Redox Biol, 2024. 69: p. 102972.

[0175] 66. Xiao, F., et al., Small Noncoding RNAome Changes During Human Bone Marrow Mesenchymal Stem Cells Senescence In Vitro. Front Endocrinol (Lausanne), 2022. 13: p. 808223.

[0176] 67. Zhou, X., et al., Mesenchymal Stem Cell Senescence and Rejuvenation: Current Status and Challenges. Front Cell Dev Biol, 2020. 8: p. 364.

[0177] 68. Goldsteins, G., et al., Deleterious role of superoxide dismutase in the mitochondrial intermembrane space. J Biol Chem, 2008. 283(13): p. 8446-52.

[0178] 69. Perry, J. J., et al., The structural biochemistry of the superoxide dismutases. Biochim Biophys Acta, 2010. 1804(2): p. 245-62.

[0179] 70. Izadpanah, R., et al., Long-term in vitro expansion alters the biology of adult mesenchymal stem cells. Cancer Res, 2008. 68(11): p. 4229-38.

[0180] 71. Huang, L.H., et al., Identification and characterization of hADSC-derived exosome proteins from different isolation methods. J Cell Mol Med, 2021 . 25(15): p. 7436-7450.

[0181] 72. Ferreira, J.V., et al., LAMP2A regulates the loading of proteins into exosomes. Sci Adv, 2022. 8(12): p. eabm1140.

[0182] 73. de la Torre Gomez, C., et al., "Exosomics"-A Review of Biophysics, Biology and Biochemistry of Exosomes With a Focus on Human Breast Milk. Front Genet, 2018. 9: p. 92.

Claims

CLAIMS1 . A method for growing cells comprising: growing a quantity of cells in a suitable growth media comprising an effective amount of a peptide comprising a lysosomal targeting motif and a domain specific for the derlin- binding region of superoxide dismutase 1 .

2. The method according to claim 1 wherein the peptide is arranged or formulated for penetration or entry into the quantity of cells.

3. The method according to claim 2 wherein the peptide is arranged for penetration or entry into the quantity of cells by further comprising a cell-penetration domain.

4. The method according to claim 3 wherein the cell penetration domain is selected from the group consisting of: cell-penetration domain of Tat peptide, penetratin domain of the antennapedia, TAT(48-60), R8 and R9.

5. The method according to claim 1 wherein the lysosomal targeting motif is the chaperone-mediated autophagy targeting motif (CTM).

6. The method according to claim 1 wherein the cells are stem cells.

7. The method according to claim 6 wherein the stem cells are human stem cells.

8. The method according to claim 7 wherein the human stem cells are human neural stem cells or human mesenchymal stem cells.

9. The method according to claim 1 wherein the cells are grown in vitro.

10. The method according to claim 7 wherein extracellular vesicles are recovered from the growing human stem cells.11 . The method according to claim 1 wherein the domain specific for the derlin- binding region of superoxide dismutase 1 is selected from the group consisting of: CT4, CT4L and CT4S.

12. The method according to claim 6 wherein proliferation and sternness of the quantity of stem cells is improved or increased compared to cells grown under similar conditions except for the presence of the peptide.

Citation Information

Patent Citations

  • Compound for treatment of neurodegenerative disease

    JP2007151478A